Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 10, 2022 16:05 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
July 20, 2022 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for...
Soleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference
July 11, 2022 16:05 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS
June 13, 2022 16:05 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for...
Soleno Therapeutics Announces Presentations at ENDO 2022
June 07, 2022 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology
May 19, 2022 16:05 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 17, 2022 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 10, 2022 16:01 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi Syndrome
May 02, 2022 16:05 ET
|
Soleno Therapeutics
Results Show Significant Improvements in Hyperphagia and PWS-Related Behaviors in DCCR-Treated Patients Presentations at the Pediatric Academic Societies 2022 Virtual Annual Meeting and Pediatric...